

## CLAIMS

1. A preparation containing Hepatocyte growth factor (HGF) as an active ingredient, and allowing an effective amount of said factor to be transported to, distributed in, and act on local tissues of a region to which it is administered and tissues around the region, while it reduces transportation, distribution and effect of the factor to the blood and other organs of the body except the region to which it is administered.

2. The preparation according to claim 1 for use in treating and preventing ischemic and arterial diseases.

3. The preparation according to claim 1 or 2 used for intramuscular administration, wherein the region to which it is administered is a muscle.

4. The preparation according to claim 1 or 2 for subcutaneous administration or external application or in the form of a cataplasm, wherein the region to which it is administered is subcutaneous or intraepidermal.

5. The preparation according to claim 3 for intramuscular administration, wherein the region to which it is administered is a skeletal or cardiac muscle.

6. The preparation according to claim 1, ~~2, 3 or 5~~, wherein its transportation to, distribution in and action on muscular tissues representing the region to which it is administered surpass its transportation to, distribution in and action on the blood, liver and kidney.

7. The preparation according to claim 1, ~~2, 3, 5 or 6~~ for intramuscular administration, wherein the maximum concentration in the blood, liver and kidney is a hundredth or less, and a concentration in muscular tissues representing the region to which it is administered is 50 times or more in comparison with the case the same dose of the preparation containing HGF as

an active ingredient is administered by intravenous bolus administration.

Q 8. The preparation according to claim 1, 2, 3, 5 or 6 for intramuscular administration, wherein AUC in the blood, liver and kidney is a fifth or less, and AUC in muscular tissues representing the region to which it is administered is 50 times or more in comparison with the case the same dose of the preparation containing HGF as an active ingredient is administered by intravenous bolus administration.

A 00762488-020504 10 9. The preparation according to claim 1, 2, 3, 5, 6, 7 or 8 for intramuscular administration for treating or preventing ischemic or arterial diseases of the heart or extremities.

10. The preparation according to claim 9 for intramuscular administration for treating or preventing ischemic or arterial diseases of the heart or extremities, wherein the region to which it is administered is a local muscle of an affected region and around it.

A 15 11. The preparation according to claim 1, 2, 3, 5, 6, 7, 8, 9 or 10 for intramuscular administration, wherein a dose is at 0.01 to 500 µg/kg;

12. The preparation according to claim 11, wherein the dose is at 0.1 to 10 µg/kg.

a 20 13. The preparation according to claim 1 ~~any one of claims 1 to 12~~, wherein the arterial diseases are arteriosclerosis obliterans.

a 14. The preparation according to claim 1 ~~any one of claims 1 to 12~~, wherein the ischemic diseases are ischemic heart diseases.

a 25 15. The preparation according to claim 1 ~~any one of claims 1 to 14~~, wherein the preparation contains HGF as an active ingredient, and does not contain any substance that binds and adsorbs HGF.

add B2